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The problem: Inefficient lung cytosol delivery
Lung epithelial cells provide structural integrity, allow gas exchange and
enhance ion and fluid transport. Damaged epithelium leads to the
development of respiratory diseases, such as chronic obstructive pulmonary
disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis, and, lately,
the 2019 coronavirus disease (COVID-19).
Effective use of macromolecular therapeutics targeting intracellular
components of the lung is severely restricted due to poor cytosolic delivery to
the respiratory epithelium (Moschos et al., 2017). Outer membrane vesicles
(OMVs) are spherical structures (20-250nm) produced by pathogenic and
commensal bacteria, when small portions of outer membrane bulge away from
the cell, pinch off, and release into the surrounding environment (Momen-
Heravi et al., 2018).
OMVs allow bacteria to interact with their environment and, as a result, exert
diverse functions such as host cell interaction and the initiation of
pathogenesis, survival during stress conditions by toxin sequestration, and
regulation of microbial interactions. These functions are afforded through
biologically active proteins and nucleic acids naturally encapsulated in these
liposome or virus-like structures. Their utility to man is well-established
through their scaled bioproduction and application in several commercially
successful vaccine preparations.
Recent production of OMVs from BL21 (DE3)-derived, LPS-deficient Escherichia
coli (Valentine et al., 2016), commercially available as ClearColi®(Mamat et al.,
2015), introduced the possibility of pathogen associated molecular pattern-free
OMVs, at least in terms of TLR4 activation.
Our solution: bioengineered microbial vesicles
Overcome cytosolic lung delivery bottlenecks by bioengineering 
LPS-free, recombinant, biocompatible OMVs biotherapeutics.
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CLONE PRODUCTION
CONCLUSIONS & FUTURE PLANSREFERENCES
- Produce ClearColi® OMVs expressing a proprietary transmembrane
protein (TMP) which facilitates active internalisation pathways across
respiratory epithelia specifically.
- Produce bioactive OMVs featuring a series of imaging reporter
functions.
- Demonstrate TMP-enhanced OMV targeting to respiratory epithelial
cells and cytosolic reporter protein delivery.
- Demonstrate functional biotherapeutic compound delivery within
respiratory epithelial cells in vitro and air-liquid interface culture.
PROJECT OBJECTIVES 
• Stage 1: Clone production
- Clone proprietary TMP, far-red fluorescence protein (tdTomato), and N- or C-
terminally-tagged TMP in BL21 (DE3) and ClearColi® E. coli.
- Optimise recombinant protein expression.
• Stage 2: Scalable production of ClearColi® OMVs
- Develop scalable OMV production methods.
- Characterise clone impact on OMV proteome, transcriptome.
• Stage 3: Evaluate cytosolic access in cellulo
- OMV cell trafficking, RNA-SEQ, and immunomodulation:
- In submerged cell culture.
- in Air Liquid Interface (ALI) primary cell culture.
• Stage 4: Demonstrate efficient cytosolic biotherapeutic delivery
- Generate therapeutic RNA and ribonucleoprotein-containing, TMP-labelled
OMVs.
- Quantify pharmacological activity in translationally relevant cell culture systems.
Figure 1. TMP and reporter-expressing ClearColi® clone generation. (A) Construct cloning methodology and (B) Gel electrophoresis to
validate the ligation into pET-28a in N- and C- terminal fashion relative to the transmembrane (TMP) protein.
Figure 2.Optimised protein expression. (A) N- and C- terminally tagged fusion constructs were demonstrated by DS-PAGE analysis and
(B) Western immunoblotting. Strong band presentation indicates the expression of fusion protein in both orientations, (C) which is
visible in the OMV fraction only in N-terminally tagged TMP preps.
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RECOMBINANT TMP-OMVs 
- Multiple methodologies have been proposed for OMV bioproduction 
(Schwechheimer and Kuehn (2015), Klimentova and Stulik (2015), Anand  
and Chaudhuri (2016).
- Tangential Flow Filtration and Ultracentrifugation return higher purity, 
scalable, and reproducible OMV preps.
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PROTEOMIC RECOMBINANT OMV ANALYSIS
Figure 3: N-terminally tagged TMP efficiently delivers protein cargo to
OMVs. Western blotting for the 30 kDa TMP in OMVs succeeds only by N-
terminal TMP tagging, simultaneously enhancing OMV transgene loading
relative to total protein content.
Figure 4: TEM analysis of bioengineered OMVs. Magnification at 100,000 x, scale
bar 50nm, 100 kV. OMV samples were diluted in PBS.
Untagged
- Eukaryotic receptor ligand TMPs can be ectopically expressed in TLR4-evading ClearColi ®
bacteria.
- N-terminal tagging enhances TMP loading onto OMV membranes but substantially alters OMV
proteome profile.
- Validation of TMP+ ClearColi® OMV loading and internalization by lung epithelial cells may
unlock oligonucleotide, ribonucleoprotein or recombinant/mRNA delivery for chronic,
hereditary, and infectious lung disease such as IPF, COPD, cystic fibrosis, and COVID-19.
Figure 5: Highly consistent recombinant OMV bioproduction. Three independent biological OMV preps were subjected to proteomic profiling to return 1100
proteins after known contaminant removal demonstrating (A) highly consistent between-replicate prep consistency by unsupervised PCA after
log2transformation and any missing value imputation prior to visualization. The relative levels of the top 50 discriminates responsible for prep
classification are show by heatmap (B) vs Uniprot protein ID. Statistically significant changes of the top 25 to discriminate marker proteins compared to
the Control OMV prep are shown highlighted (C) underscoring the unexpected level of recombinant OMV proteomic diversity resulting through single
recombinant protein production, validating the need for comprehensive OMV profiling prior to biological use.
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